“AIDS at a Crossroads:” Highlights from the 2024 UNAIDS Report

Abstract

Get full access to this article

View all access options for this article.

References

Laurence

. “The path that ends AIDS:” National and international politics in conflict with treatment and prevention science. AIDS Patient Care STDS, 2023; 37(11):505–506.

Laurence

. Intersecting pandemics of epidemiology, inequality, genetics, and immunology: COVID-19 and AIDS. AIDS Patient Care STDS, 2022; 36(5):169–171.

UNAIDS. The urgency of now: AIDS at a crossroads—2024 global AIDS update. Available from: https://www.unaids.org/en/resources/documents/2024/global-aids-update-2024

Bekker

L-G

, Das

, Karim

, et al. PURPOSE 1 Study Team. Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women. N Engl J Med, 2024; doi: 10.1056/NEJMoa2407001

Griffin

DWJ

, Hoy

, McMahon

. Long-acting cabotegravir PrEP: A time for cautious optimism. Lancet HIV, 2023; 10(12):e756–e757.

Beyrer

, Tomaras

, Gelderblom

, et al. Is HIV epidemic control by 2030 realistic? Lancet HIV, 2024; 11(7):e489–e494.